Life Sciences Archive » October, 2010

Life Sciences - October, 2010

186 articles

• Discovery Rule Applies To Stryker Pain Pumps: Judge
• Hikma Buys Baxter's Injectibles Business For $112M
• Novartis, Watson End Suit Over Enablex ANDA
• Chem Rx Auction Canceled Due To Low Bid Turnout
• Ex-Pfizer Exec Takes Genotropin Suit To 1st Circ.
• Sandoz Pulls Methotrexate Lots Over Vial Defects
• Merck Sets Aside $950M For Federal Vioxx Settlement
• AGA Medical Investor Sues Over $1.3B St. Jude Deal
• French Court Sides With Novartis In J&J Patent War
• DOJ, Attys Duel Over Sentence For Convicted Fraudster
• St. Jude Surgical Patent Withstands ACI Dismissal Bid
• Targeting Health Care Execs And Managers
• Ex-Safescript CEO Gets 30 Months For Insider Trading
• Zydus Fights For Right To Make Generic Strattera
• Neurovision Wins $60M Verdict In Trademark Suit
• 1 Size Doesn't Fit All In Patent Trials
• Creditors Fight Chem Rx's Asset Sale Plans
• Teva To Acquire Theramex in €265M Deal
• Shearman Reps Boston Sci In $2B Unit Sale To Stryker
• Customs Improperly Classified Surgical Lamps: CIT
• GSK Must Face Wellbutrin Consumer Antitrust Suit
• AstraZeneca Targets Watson Over Crestor NDA
• Pharmacists Group Loses Appeal Of EU Antitrust Raid
• Wyeth, Schwarz Escape Reglan Failure-To-Warn Suit
• Australian Watchdog Delays Aspen's Sigma Bid
• Novartis Sues Apotex To Block Generic Exelon
• Intel, Express Scripts Settle Row Over 'Intellact' Mark
• Motorola Latest Target In False Marking Suit Wave
• FDA Warns Drug Co. Over Misleading Info On Website
• Pfizer Faces Italian Antitrust Probe Over Xalatan Patent
• Bayer To Pay 3 States $3.3M To End Vitamin Claims
• GSK To Pay Record $750M Whistleblower Settlement
• FDA Warns Mead Johnson Over Enfamil Packaging
• Abbott, WARF Hit Anchen With Zemplar Patent Suit
• 2nd Circ. Quashes Philips Atty's Wrongful Firing Suit
• Amphastar Sues FDA Over Raw Heparin Shipments
• King Pharma Drug Reps Sue For Overtime Pay
• Actavis Recalls Pain Patches Over Dosage Fears
• US Attys Eye Canada As Fertile Class Action Ground
• Plaintiff Rejects New Verdict In Merck Fosamax Case
• Pharma Industry Dominates 2010 FCA Payouts
• Carlyle Weighs $3B Buyout Of CommScope
• Judge Tosses FCA Suit Against Medco Health
• Humana Tries To Snuff Qui Tam Medicare Fraud Case
• Occlutech Win In Dutch Feud With AGA Medical Stands
• Ex-Trader Still On Hook For Tips From Insider's Wife
• 1st Circ. Affirms Liability Of Infomercial Producers
• Winston & Strawn Nets Cadwalader M&A Pro
• Suit Says GE CT Scans Blast Patients With Radiation
• 9th Circ. Tosses Amgen Off-Label Marketing MDL
• FDA Issues Alert Over Chinese Crospovidone
• FDA Strengthens Warning Label On Roche HIV Drug
• 2nd Circ. Considers Reinstating Fosamax Witness
• Wyeth Loses Bid To Keep Effexor Deals Under Wraps
• Mentor Investors' Suit Over $1B J&J Merger Tossed
• Mylan Takes Bid For Paxil Injunction To 3rd Circ.
• DOJ, US Atty Subpoena GSK Over Avandia, HIV Drugs
• Judge Reverses Verdict In KCI Wound Therapy IP Suit
• Mutual, Hikma Settle Suit Over Unapproved Gout Drug
• ProThera Must Face Merck Unit's Folate Ad Claims
• FDA Wants New Warnings On Prostate Cancer Drugs
• Prempro Use May Double Breast Cancer Risk: Study
• Lilly Sues Accord Over Gemzar ANDA
• Mylan Attacks Newly Issued Oracea Patent
• 8th Circ. To Rehear Catheter Antitrust Suit Against Bard
• Skadden Reps Pfizer In $240M Deal For Teuto Stake
• Common Benefit Attys To Get $315M From Vioxx Deal
• Nurse, Dr.'s Sentences Upheld In Medicare Scam Case
• McKesson To Pay Conn. $15M To Settle AWP Suit
• Pfizer Cleared In $3.5M Prempro Trial
• Fosamax Plaintiff's Attorney Appeals Sanctions
• J&J Unit Recalls More Tylenol For Musty Odor
• Pharmacy Seeks To Send Provigil Suit To State Court
• Wellbutrin Users Seek To Revive Class Cert. Bid
• Baxter Settles Lab Tech OT Action For $2.6M
• Prosecutors Refuse To Give FDA Docs To Stryker
• Colgate Fires Back In GSK's Toothpaste IP Suit
• Sanofi, Bristol-Myers Win $442M In Plavix Patent Suit
• Patent Reform's Effects On Hatch-Waxman Litigants
• FDA Panel OKs Use Of Anemia Drugs, Despite Study
• Idaho Settles AWP Claims With Sandoz For $1.7M
• Genzyme Hits Medicis With IP Suit Over Wrinkle Fillers
• Supreme Court Rebuffs Spat Over Wound Therapy IP
• Gibson Dunn Reps St. Jude In $1.3B AGA Medical Deal
• King's Board Cashing In On $3.6B Pfizer Deal: Suit
• Nigerians Win Discovery Bid In Suits Over Pfizer Trials
• 'Printed Publications' In A Digital Age
• SEC Wins Fraud Suit Against Troubled Drug Co.
• 6th Circ. Won't Rehear Wyeth Diet Pill Case En Banc
• 8th Circ. Affirms Preemption Ruling In Medtronic MDL
• DOJ Antitrust Division Enlists Cravath Partner
• Teleflex Can't Toss All Claims In Kan. Cleanup Fight
• Warner Chilcott, Lupin Settle Birth Control IP Dispute
• Pozen's Suit Over Treximet ANDAs Stays Intact
• La. Jury Hits J&J With $258M Verdict In Risperdal Suit
• 5 Tricks For Deposing A Class Certification Expert
• UK Fines Reckitt $16M For Thwarting Generic Meds
• FDA To Assess Anemia Drug Risks In Kidney Patients
• FDA To Yank Marketing Approval For Menaflex Device
• AARP Joins Whistleblower Suit Against Stent Makers
• CVS To Pay $75M For Admitted Sale Of Meth Ingredient
• KV Settles Promote Innovation False Marking Suit
• Ivera Sues Hospira Over Medical Cleaning Patent
• US Wins Bid To Intervene In Qui Tam Wyeth Drug Suit
• The FDA's New New Drug Safety Reporting Plan
• Medtronic Settles Sprint Fidelis MDL For $268M
• EPA Ups Ethanol Allowance, Draws Ire From Both Sides
• 1st Circ. Overturns Toss Of Genzyme D&O Coverage Suit
• Howmedica Polymers Patents Invalid: Fed Circ.
• St. Jude Tries To Block BSC's Poached Worker Suit
• FDA To Revise Warning Label On Bone Drugs
• Celgene Sues Natco To Block Generic Revlimid
• House Reps Call For Balance In 510(k) Overhaul
• 3rd Circ. Says Suit Over HIV Drug IP Belongs In France
• 4 Steps To Take When Your Client Gets Subpoenaed
• A Securities Litigator's Guide To D&O Insurance, Part I
• Cobalt Released From Sepracor Suit Over Sleep Drug
• High Court Weighs Vaccine Injury Preemption
• Teva Fails To Uncover Plans For Generic Copaxone
• Merck Targets Experts In Next Fosamax Bellwether
• Becton Fights Antitrust Claims By Rival Syringe Maker
• Roche Fires Back At SG In Contractor IP Rights Case
• High Court Snubs Drug Cos.' Appeal Of HRT Cases
• Impax Settles Cephalon Suit Over Generic Amrix
• Cadwalader Reps Pfizer In $3.6B King Pharma Buy
• Russian Court Nixes Plastic Co.'s Competition Case
• Pfizer To Pay $3.8M Over Girl's Death In Dilantin Suit
• Mayer Brown Nabs Solvay Pharma GC
• Purdue Sues Hospira To Block New Version Of Dilaudid
• Avandia ERISA Class Actions Consolidated
• Tensions Simmer In Sanofi, Genzyme Bid Battle
• Takeda, Wockhardt Settle Feud Over Generic Actos
• Abbott To Pull Meridia In US Over Heart Risks
• FDA To Revamp Regulatory Science Agenda
• Settlement Docs Off-Limits In Rituxan Fraud Suit
• New DataTern IP Suit Targets Aflac, Lilly, Others
• Novartis Prevails In 2nd Trial Over Bone Drug Liability
• Pfizer Recalls 191,000 Lipitor Bottles Due To Odor
• Cravath, Weil Advise J&J In €1.75B Offer For Crucell
• Conceptus Waived Privilege For Prior Art Letter: Judge
• Volcano Can Use Confidential Info In Secrets Spat
• Angiotech Accused Of Breaching Quill Merger Deal
• Endo, Watson Settle Litigation Over Opana ER Generic
• Chem Rx's Bidding Procedures, Breakup Fee OK'd
• Consumers Target J&J Unit Over Listerine Marketing
• The Patent System Pendulum Revisited
• Pfizer Hits Lupin With 2nd Suit Over Lyrica ANDA
• Indirect Wellbutrin Buyers Denied Cert. Against GSK
• Allergan Sues Watson, Paddock Over Generic Sanctura
• Fed. Circ. Revives Teva's Suit Over Aricept Patents
• Novo Can't Shake Bid To Invalidate Prandin Patent
• Brazilians' Enviro Claims Don't Stand In US, Judge Says
• Chinese Co. Shells Out $7.5M For Illegal HGH Sales
• Coke, LG, Others Targeted In Web Data Patent Suit
• Generic Preemption Issue At Play In 9th Circ.
• Toshiba, Wistron Settle Laptop Patent Dispute
• Trubion Investor Sues To Halt $135M Sale To Emergent
• Teva Sues Mylan, Others Over Proposed Azilect Generic
• CB Richard Says Workers In China Paid Local Officials
• 3 Perrigo Board Members Walk From ARS Class Suit
• Stryker Says FDA Has Docs That Will Exonerate It
• Lilly Targets Dr. Reddy's Over Gemzar ANDA
• FDA Warns Gilead Over Drug Plant Problems
• Judge Merges Suits Over Provigil Pay-For-Delay Deals
• 2nd Circ. Axes 8 Zyprexa Suits Against Eli Lilly
• Trust Your Doctor, Not The 'Net
• Character Testimony Bid Nixed In Insider Trading Case
• Synthes To Pay $24M For Illegal Bone Cement Tests
• Judge Cuts Fosamax Award From $8M To $1.5M
• Sanofi Takes $18.5B Bid To Genzyme Shareholders
• Streck Triumphs In Hematology IP Fight Against Rival
• Chem Rx Gets More Time To File Ch. 11 Plan
• Gilead Sues Sigmapharm Over Hepatitis B Generic
• Supreme Court Asks US To Weigh In On Loss Causation
• FDA Seeks More Info On J&J's New Pain Drug
• How New USPTO Guidelines Clarify Obviousness Issues
• How Certain Products Can Be The Same, But Different
• Naturex Agrees To Stop Violating Mars Flavanol Patents
• Walgreen Beats Shareholder Suit Over Analyst Report
• Medtronic Settles Patent Spat Over Stents
• UK Court To Hear AstraZeneca's $10M Contract Suit
• Jury To Decide Roche Battle Over Generic Boniva
• AstraZeneca Targets Torrent Again Over Seroquel ANDA
• Lead Plaintiff In Eli Lilly FLSA Suit Still Out
• Pharmacy Class Blasts CVS For Misusing Patient Info
• Guide Flow Sues Bard, Others Over Catheter Patent